Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 0 up to and including 18 years of age~* Undergoing elective cardiopulmonary bypass surgery~* Are planned to have a chest tube placed in the operating room prior to chest closure~Exclusion Criteria:~* \>/=19 years of age~* Preterm infants (less than 38-week gestational age at time of surgery)~* On extracorporeal membrane oxygenation (ECMO) or ventricular assist device prior to surgery~* Family requests limitation of blood products (i.e. Jehovah's Witness)~* Congenital bleeding disorder~* Are planned to require ECMO post-op~* Previously enrolled in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Pathogen-reduced (PR) platelet transfusions (Type: ACTIVE_COMPARATOR): FDA approved and already used in this patient population
- Large volume delayed sampling - LVDS (Type: ACTIVE_COMPARATOR): FDA approved and already used in this patient population
- No platelet transfusion (Type: NO_INTERVENTION): Subject will not receive a platelet transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).